Hypertension guidelines: Treat patients, not numbers

REFERENCES

1. ↵
   1. Whelton PK,
   2. Carey RM,
   3. Aronow WS,
   4. et al

   . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006

   OpenUrlFREE Full Text
2. ↵
   1. Chobanian AV,
   2. Bakris GL,
   3. Black HR,
   4. et al

   . The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19):2560–2572. doi:10.1001/jama.289.19.2560

   OpenUrlCrossRefPubMed
3. ↵
   1. Go AS,
   2. Bauman MA,
   3. King SM,
   4. et al

   . An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension 2014; 63(4):878–885. doi:10.1161/HYP.0000000000000003

   OpenUrlCrossRefPubMed
4. ↵
   1. James PA,
   2. Oparil S,
   3. Carter BL,
   4. et al

   . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5):507–520. doi:10.1001/jama.2013.284427

   OpenUrlCrossRefPubMed
5. ↵
   1. Wright JT Jr.,
   2. Fine LJ,
   3. Lackland DT,
   4. Ogedegbe G,
   5. Dennison Himmelfarb CR

   . Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 2014; 160(7):499–503. doi:10.7326/M13-2981

   OpenUrlCrossRefPubMed
6. ↵
   1. Weber MA,
   2. Schiffrin EL,
   3. White WB,
   4. et al

   . Notice of duplicate publication [duplicate publication of Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 2014; 16(1):14–26. doi:10.1111/jch.12237] J Hypertens 2014; 32(1):3–15. doi:10.1097/HJH.0000000000000065

   OpenUrlCrossRefPubMed
7. ↵
   1. Rosendorff C,
   2. Lackland DT,
   3. Allison M,
   4. et al

   . Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens 2015; 9(6):453–498. doi:10.1016/j.jash.2015.03.002

   OpenUrlCrossRefPubMed
8. ↵
   1. de Boer IH,
   2. Bangalore S,
   3. Benetos A,
   4. et al

   . Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care 2017; 40(9):1273–1284. doi:10.2337/dci17-0026

   OpenUrlFREE Full Text
9. ↵
   1. Qaseem A,
   2. Wilt TJ,
   3. Rich R,
   4. Humphrey LL,
   5. Frost J,
   6. Forciea MA

   . Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2017; 166(6):430–437. doi:10.7326/M16-1785

   OpenUrlCrossRefPubMed
10. ↵
    1. The Trials of Hypertension Prevention Collaborative Research Group

    . Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in over-weight people with high normal blood pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med 1997; 157(6):657–667. pmid:9080920

    OpenUrlCrossRefPubMed
11. ↵
    1. He J,
    2. Whelton PK,
    3. Appel LJ,
    4. Charleston J,
    5. Klag MJ

    . Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35(2):544–549. pmid:10679495

    OpenUrlAbstract/FREE Full Text
12. ↵
    1. Sacks FM,
    2. Svetkey LP,
    3. Vollmer WM,
    4. et al

    . Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344(1):3–10. doi:10.1056/NEJM200101043440101

    OpenUrlCrossRefPubMed
13. ↵
    1. Blackwell DL,
    2. Lucas JW,
    3. Clarke TC

    . Summary health statistics for US adults: National Health Interview Survey, 2012. National Center for Health Statistics. Vital Health Stat 10; 2014(260):1–161. pmid:24819891

    OpenUrlPubMed
14. ↵
    1. Muntner P,
    2. Carey RM,
    3. Gidding S,
    4. et al

    . Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. J Am Coll Cardiol 2018; 71(2):109–118. doi:10.1016/j.jacc.2017.10.073

    OpenUrlFREE Full Text
15. ↵
    1. SPRINT Research Group
    2. Wright JT Jr.,
    3. Williamson JD,
    4. Whelton PK,
    5. et al

    . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373(22):2103–2116. doi:10.1056/NEJMoa1511939

    OpenUrlCrossRefPubMed
16. ↵
    1. Bress AP,
    2. Kramer H,
    3. Khatib R,
    4. et al

    . Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: Projections from NHANES (National Health and Nutrition Examination Survey). Circulation 2017; 135(17):1617–1628. doi:10.1161/CIRCULATIONAHA.116.025322

    OpenUrlAbstract/FREE Full Text
17. ↵
    1. Williamson JD,
    2. Supiano MA,
    3. Applegate WB,
    4. et al

    . Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. JAMA 2016; 315:(24)2673–2682. doi:10.1001/jama.2016.7050

    OpenUrlCrossRefPubMed
18. ↵
    1. Beddhu S,
    2. Rocco MV,
    3. Toto R,
    4. et al

    . Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial. Ann Intern Med 2017; 167(6):375–383. doi:10.7326/M16-2966

    OpenUrlCrossRefPubMed
19. ↵
    1. Brunström M,
    2. Carlberg B

    . Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med 2018; 178(1):28–36. doi:10.1001/jamainternmed.2017.6015

    OpenUrlCrossRefPubMed
20. ↵
    1. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension

    . Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24):3255–3264. pmid:2046107

    OpenUrlCrossRefPubMed
21. ↵
    1. Bulpitt CJ,
    2. Beckett NS,
    3. Cooke J,
    4. et al

    . Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21(12):2409–2417. doi:10.1097/01.hjh.0000084782.15238.a2

    OpenUrlCrossRefPubMed
22. ↵
    1. Liu L,
    2. Zhang Y,
    3. Liu G,
    4. et al

    . The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23(12):2157–2172. pmid:16269957

    OpenUrlCrossRefPubMed
23. ↵
    1. JATOS Study Group

    . Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31(12):2115–2127. doi:10.1291/hypres.31.2115

    OpenUrlCrossRefPubMed
24. ↵
    1. Ogihara T,
    2. Saruta T,
    3. Rakugi H,
    4. et al

    . Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010; 56(2):196–202. doi:10.1161/HYPERTENSIONAHA.109.146035

    OpenUrlAbstract/FREE Full Text
25. ↵
    1. Ettehad D,
    2. Emdin CA,
    3. Kiran A,
    4. et al

    . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387(10022):957–967. doi:10.1016/S0140-6736(15)01225-8

    OpenUrlCrossRefPubMed
26. ↵
    1. Sleight P

    . The HOPE study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1(1):18–20. doi:10.3317/jraas.2000.002

    OpenUrlCrossRefPubMed
27. ↵
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200):253–259. pmid:10675071

    OpenUrlCrossRefPubMed
28. ↵
    1. Yusuf S,
    2. Bosch J,
    3. Dagenais G,
    4. et al

    . Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374(21):2021–2031. doi:10.1056/NEJMoa1600176

    OpenUrlCrossRefPubMed
29. ↵
    1. Yusuf S,
    2. Lonn E,
    3. Pais P,
    4. et al

    . Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016; 374(21):2032–2043. doi:10.1056/NEJMoa1600177

    OpenUrlCrossRefPubMed
30. ↵
    1. Lonn EM,
    2. Bosch J,
    3. López-Jaramillo P,
    4. et al

    . Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374(21):2009–2020. doi:10.1056/NEJMoa1600175

    OpenUrlCrossRefPubMed
31. ↵
    1. Bundy JD,
    2. Li C,
    3. Stuchlik P,
    4. et al

    . Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol 2017; 2(7):775–781. doi:10.1001/jamacardio.2017.1421

    OpenUrlCrossRefPubMed
32. ↵
    1. Emdin CA,
    2. Rahimi K,
    3. Neal B,
    4. Callender T,
    5. Perkovic V,
    6. Patel A

    . Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313(6):603–615. doi:10.1001/jama.2014.18574

    OpenUrlCrossRefPubMed
33. ↵
    1. ACCORD Study Group
    2. Cushman WC,
    3. Evans GW,
    4. Byington RP,
    5. et al

    . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17):1575–1585. doi:10.1056/NEJMoa1001286

    OpenUrlCrossRefPubMed
34. ↵
    1. SPS3 Study Group
    2. Benavente OR,
    3. Coffey CS,
    4. Conwit R,
    5. et al

    . Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382(9891):507–515. doi:10.1016/S0140-6736(13)60852-1

    OpenUrlCrossRefPubMed